Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced it will hold an analyst and investor webcast on Wednesday, September 28, 2022. The event will highlight WVE-006, Wave’s A-to-I RNA base editing oligonucleotide (“AIMer”) candidate for the treatment of alpha-1 antitrypsin deficiency (AATD), provide perspectives from an expert in AATD, and outline future therapeutic applications of Wave’s best-in-class RNA editing capability.
Related news for (WVE)
- Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA’s Annual Scientific Sessions
- Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
- Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
- Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update